Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1989 Dec;57(12):3869–3875. doi: 10.1128/iai.57.12.3869-3875.1989

Resistance of highly pathogenic Naegleria fowleri amoebae to complement-mediated lysis.

L Y Whiteman 1, F Marciano-Cabral 1
PMCID: PMC259919  PMID: 2807551

Abstract

Weakly pathogenic and nonpathogenic Naegleria spp. are readily lysed by human and guinea pig complement. Highly pathogenic Naegleria fowleri are resistant to complement-mediated lysis. Electrophoretic analysis of normal human serum (NHS) incubated with pathogenic or nonpathogenic Naegleria spp. demonstrates that amoebae activate the complement cascade, resulting in the production of C3 and C5 complement cleavage products. To determine whether surface constituents play a role in resistance to complement lysis, trophozoites of Naegleria spp. were subjected to enzymatic treatments prior to incubation in NHS. Treatment of trophozoites with papain or trypsin for 1 h, but not with neuraminidase, increased susceptibility of highly pathogenic Naegleria fowleri to complement lysis. Treatment of trophozoites with actinomycin D or cycloheximide during incubation with NHS or pretreatment with various protease inhibitors for 4 h did not increase the susceptibility of N. fowleri amoebae to lysis. Neither a repair process involving de novo protein synthesis nor a complement-inactivating protease appears to account for the increased resistance of N. fowleri amoebae to complement-mediated lysis.

Full text

PDF
3869

Images in this article

3871Image
on p.3871
3872Image
on p.3872

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bordier C. The promastigote surface protease of Leishmania. Parasitol Today. 1987 May;3(5):151–153. doi: 10.1016/0169-4758(87)90199-2. [DOI] [PubMed] [Google Scholar]
  2. Bouvier J., Etges R., Bordier C. Identification of the promastigote surface protease in seven species of Leishmania. Mol Biochem Parasitol. 1987 May;24(1):73–79. doi: 10.1016/0166-6851(87)90117-4. [DOI] [PubMed] [Google Scholar]
  3. Calderon J., Schreiber R. D. Activation of the alternative and classical complement pathways by Entamoeba histolytica. Infect Immun. 1985 Nov;50(2):560–565. doi: 10.1128/iai.50.2.560-565.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chaudhuri G., Chang K. P. Acid protease activity of a major surface membrane glycoprotein (gp63) from Leishmania mexicana promastigotes. Mol Biochem Parasitol. 1988 Jan 1;27(1):43–52. doi: 10.1016/0166-6851(88)90023-0. [DOI] [PubMed] [Google Scholar]
  5. Cline M., Marciano-Cabral F., Bradley S. G. Comparison of Naegleria fowleri and Naegleria gruberi cultivated in the same nutrient medium. J Protozool. 1983 May;30(2):387–391. doi: 10.1111/j.1550-7408.1983.tb02936.x. [DOI] [PubMed] [Google Scholar]
  6. Deguchi M., Gillin F. D., Gigli I. Mechanism of killing of Giardia lamblia trophozoites by complement. J Clin Invest. 1987 May;79(5):1296–1302. doi: 10.1172/JCI112952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Devine D. V., Falk R. J., Balber A. E. Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense. Infect Immun. 1986 Apr;52(1):223–229. doi: 10.1128/iai.52.1.223-229.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fearon D. T. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971–1975. doi: 10.1073/pnas.75.4.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hill D. R., Burge J. J., Pearson R. D. Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum. J Immunol. 1984 Apr;132(4):2046–2052. [PubMed] [Google Scholar]
  10. Hoffman E. M. Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry. 1969 May;6(3):391–403. doi: 10.1016/0019-2791(69)90296-1. [DOI] [PubMed] [Google Scholar]
  11. Huldt G., Davies P., Allison A. C., Schorlemmer H. U. Interactions between Entamoeba histolytica and complement. Nature. 1979 Jan 18;277(5693):214–216. doi: 10.1038/277214a0. [DOI] [PubMed] [Google Scholar]
  12. Kalb V. F., Jr, Bernlohr R. W. A new spectrophotometric assay for protein in cell extracts. Anal Biochem. 1977 Oct;82(2):362–371. doi: 10.1016/0003-2697(77)90173-7. [DOI] [PubMed] [Google Scholar]
  13. Kazatchkine M. D., Fearon D. T., Austen K. F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol. 1979 Jan;122(1):75–81. [PubMed] [Google Scholar]
  14. Kipnis T. L., David J. R., Alper C. A., Sher A., da Silva W. D. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A. 1981 Jan;78(1):602–605. doi: 10.1073/pnas.78.1.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kipnis T. L., Krettli A. U., Dias da Silva W. Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol. 1985 Aug;22(2):217–226. doi: 10.1111/j.1365-3083.1985.tb01874.x. [DOI] [PubMed] [Google Scholar]
  16. Kipnis T. L., Sucupira M., da Silva W. D. Transformation of Trypanosoma cruzi trypomastigote bloodstream forms by immune IgM and its Fab mu fragment into activators of the alternative complement pathway. Braz J Med Biol Res. 1987;20(1):105–114. [PubMed] [Google Scholar]
  17. Marciano-Cabral F. M., Patterson M., John D. T., Bradley S. G. Cytopathogenicity of Naegleria fowleri and Naegleria gruberi for established mammalian cell cultures. J Parasitol. 1982 Dec;68(6):1110–1116. [PubMed] [Google Scholar]
  18. Marciano-Cabral F. Biology of Naegleria spp. Microbiol Rev. 1988 Mar;52(1):114–133. doi: 10.1128/mr.52.1.114-133.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Marciano-Cabral F., Cline M. L., Bradley S. G. Specificity of antibodies from human sera for Naegleria species. J Clin Microbiol. 1987 Apr;25(4):692–697. doi: 10.1128/jcm.25.4.692-697.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Marciano-Cabral F., Stanitski S., Radhakrishna V., Bradley S. G. Characterization of a neutral aminoacyl-peptide hydrolase from Naegleria fowleri. J Protozool. 1987 May;34(2):146–149. doi: 10.1111/j.1550-7408.1987.tb03151.x. [DOI] [PubMed] [Google Scholar]
  21. Medof M. E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984 Nov 1;160(5):1558–1578. doi: 10.1084/jem.160.5.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Meri S., Richaud G., Linder E. Complement activation by antigenic fractions of Entamoeba histolytica. Parasite Immunol. 1985 Mar;7(2):153–164. doi: 10.1111/j.1365-3024.1985.tb00066.x. [DOI] [PubMed] [Google Scholar]
  23. Morgan B. P., Dankert J. R., Esser A. F. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987 Jan 1;138(1):246–253. [PubMed] [Google Scholar]
  24. Mosser D. M., Edelson P. J. The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes. J Immunol. 1985 Oct;135(4):2785–2789. [PubMed] [Google Scholar]
  25. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  26. Ortiz-Ortiz L., Capin R., Capin N. R., Sepúlveda B., Zamacona G. Activation of the alternative pathway of complement by Entamoeba histolytica. Clin Exp Immunol. 1978 Oct;34(1):10–18. [PMC free article] [PubMed] [Google Scholar]
  27. Pangburn M. K., Müller-Eberhard H. J. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A. 1978 May;75(5):2416–2420. doi: 10.1073/pnas.75.5.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Reed S. L., Curd J. G., Gigli I., Gillin F. D., Braude A. I. Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica. J Immunol. 1986 Mar 15;136(6):2265–2270. [PubMed] [Google Scholar]
  29. Rimoldi M. T., Sher A., Heiny S., Lituchy A., Hammer C. H., Joiner K. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proc Natl Acad Sci U S A. 1988 Jan;85(1):193–197. doi: 10.1073/pnas.85.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schenkein H. A., Ruddy S. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan. J Immunol. 1981 Jan;126(1):7–10. [PubMed] [Google Scholar]
  31. Schuster F. L. Intranuclear virus-like bodies in the amoeboflagellate Naegleria gruberi. J Protozool. 1969 Nov;16(4):724–727. doi: 10.1111/j.1550-7408.1969.tb02333.x. [DOI] [PubMed] [Google Scholar]
  32. Schönermark S., Rauterberg E. W., Shin M. L., Löke S., Roelcke D., Hänsch G. M. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol. 1986 Mar 1;136(5):1772–1776. [PubMed] [Google Scholar]
  33. Whiteman L. Y., Marciano-Cabral F. Susceptibility of pathogenic and nonpathogenic Naegleria spp. to complement-mediated lysis. Infect Immun. 1987 Oct;55(10):2442–2447. doi: 10.1128/iai.55.10.2442-2447.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES